After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. Still, questions continue to swirl about an evolving ...

The market response to Vabysmo has been robust and impressive. In 2023, Vabysmo’s global sales reached US$ 2.7 Billion, indicating strong market penetration and acceptance. This growing ...

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the data for ...

Roche’s Genentech unit has said will reintroduce its Susvimo ... and Roche’s new drug Vabysmo (faricimab), currently require injections every month, at least initially. Thereafter, dosing ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out in arenas beyond just prescription counts and sales numbers.

Supply for Vabysmo PFS will become available to Canadian ophthalmologists and their patients in the coming months. Roche Canada is committed to continuing to work with the provincial and ...

Xoma earns a 0.5% royalty on Vabysmo, and the consensus projections indicate substantial sales growth from $5.0 billion in 2025 to $7.9 billion by 2030, translating into royalties of $25 million ...

Roche (RHHBY) announced that the European Medicines Agency, EMA, has approved Vabysmo 6.0 mg single-dose prefilled syringe, PFS, for use in the treatment of neovascular or ‘wet’ age-related ...

However, Eylea’s sales have been under pressure in the last couple of years due to competition from Roche’s RHHBY Vabysmo. The uptake of Roche’s Vabysmo has been phenomenal. Roche has ...